In hepatocellular carcinoma (HCC), glypican-3 knockdown reduces the lactylation of c-myc and further reduces the protein stability and expression of c-myc, thereby inhibiting the progression of liver cancer [94]. The gene discussed is MYC; the disease is hepatocellular carcinoma.